Matthew Smith
About Matthew Smith
Matthew Smith serves as the Associate Director of Process Development and Data Analytics at Kite Pharma, where he coordinates commercial process monitoring reports for production facilities. He has extensive experience in process validation and statistical process control, with a background in chemical engineering and biotechnology.
Work at Kite Pharma
Matthew Smith serves as the Associate Director of Process Development and Data Analytics at Kite Pharma, a role he has held since 2022. In this position, he collaborates with site and network subject matter experts (SMEs) to coordinate the completion of commercial process monitoring reports for multiple production facilities. His expertise in process development and data analytics contributes to the advancement of Kite Pharma's initiatives in the biopharmaceutical sector.
Previous Experience in Biopharmaceuticals
Before joining Kite Pharma, Matthew Smith worked at Novartis Gene Therapies as a Principal Scientist in Technical Development for six months in 2021. Prior to that, he held the position of Senior Manager in Process Analytics at Novartis Gene Therapies from 2019 to 2021. His experience also includes a role as Principal Scientist in Process Sciences at Novartis Vaccines from 2012 to 2014, and as Senior Technical Steward from 2014 to 2015, both in Holly Springs, North Carolina.
Education and Expertise
Matthew Smith earned his Ph.D. in Chemical Engineering with a minor in Biotechnology from North Carolina State University. He also holds a Master’s Degree in Chemical Engineering and a Bachelor’s Degree in Chemical Engineering with a bioscience option, both from the same institution. His academic background provides a strong foundation for his expertise in Stage 3 process validation principles and statistical process control (SPC) tools and methodologies.
Experience at Seqirus
Matthew Smith worked as a Senior Scientist at Seqirus, a CSL Company, from 2015 to 2019 in Holly Springs, North Carolina. During his tenure, he was part of the Statistical Sciences & Process Analytics group, where he supported a commercial CAR T therapy for diffuse large B-cell lymphoma. His role involved significant contributions to process analytics and validation efforts within the organization.